Positive results for clinical trial in progressive MS
Source MS Society: Researchers in the US have proclaimed their initial test of ibudilast for MS a success.
Positive results for clinical trial in progressive MS Read More »
Research
Swiss Genomics Firm, Biogen and Microsoft Team Up to Treat Multiple Sclerosis
Source Labiotech.eu BC Platforms and Microsoft will be working with Biogen and the Accelerated Cure Project to study the genetics of multiple sclerosis and accelerate research.
Swiss Genomics Firm, Biogen and Microsoft Team Up to Treat Multiple Sclerosis Read More »
3D printing brain scans helps doctors with a tricky diagnosis
Source Tech Crunch: When there’s a problem in the brain, it pays to be precise — every millimeter counts with something like a tumor or blocked artery.
3D printing brain scans helps doctors with a tricky diagnosis Read More »
Long-term Lemtrada Treatment Benefits Demonstrated in Extension Study
Source Multiple Sclerosis News Today: A five-year study demonstrated that Sanofi-Genzyme’s Lemtrada (alemtuzumab) provides long-term benefits for relapsing-remitting multiple sclerosis patients, reducing relapse rates and preventing the progression of the disease. Importantly, most patients required only the standard two-phase treatment course. Few needed additional courses because of relapse or new brain lesions. Read on.
Long-term Lemtrada Treatment Benefits Demonstrated in Extension Study Read More »
New study to look at impact of early treatment with aggressive DMTs
Source MS Society: A new study will investigate whether early treatment with aggressive disease modifying therapies (DMTs) could benefit people with MS.
New study to look at impact of early treatment with aggressive DMTs Read More »
Disarm Therapeutics to Begin Developing Therapy that Prevents Axonal Degeneration
Source Multiple Sclerosis News Today: Disarm Therapeutics has completed the first round of financing to develop a compound that prevents axonal degeneration in patients with multiple sclerosis (MS) and other neurodegenerative conditions.
Disarm Therapeutics to Begin Developing Therapy that Prevents Axonal Degeneration Read More »
MS Society Research Talk 13th November
Research Talk Date: Monday 13th November 2017, Time: 10:30 – 13:30 Venue: The Salvation Army Hall Chalfont Close, Lower Earley, RG6 5HZ
MS Society Research Talk 13th November Read More »
European Commission reverses decision on drug, following QMUL research
Source Queen Mary University of London: A drug for multiple sclerosis (MS) has been granted a license by the European Commission, following evidence from Queen Mary University of London (QMUL) that it improves patients’ quality of life and is safer than previously thought.
European Commission reverses decision on drug, following QMUL research Read More »
Gut Microbes May Influence Multiple Sclerosis Progression
Source University of California San Francisco: Researchers at UC San Francisco have identified specific gut microbes associated with multiple sclerosis (MS) in human patients, and show that these microbes take part in regulating immune responses in mouse models of the disease.
Gut Microbes May Influence Multiple Sclerosis Progression Read More »
Cladribine: NICE looking at new treatment for MS
Source MS Society: The European Medicines Agency (EMA) has licensed cladribine (also known as Mavenclad) to treat people with highly active relapsing MS. The National Institute for Health and Care Excellence (NICE) will now decide whether to make it available on the NHS in England and Wales. The Scottish Medicines Consortium (SMC) will decide for Scotland. How does it
Cladribine: NICE looking at new treatment for MS Read More »